Instrument Inactif

Autres langues EXOPHARM

Actions

EX1

AU0000030975

Autres langues

29/05	49,873,318 Ordinary Shares of Exopharm Limited are subject to a Lock-Up Agreement Ending on 29-MAY-2026.
29/05	204,251,170 Options of Exopharm Limited are subject to a Lock-Up Agreement Ending on 29-MAY-2026.
08/10/24	Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2024
30/09/24	Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2024
01/05/24	232,125,358 Options of Exopharm Limited are subject to a Lock-Up Agreement Ending on 1-MAY-2025.
01/05/24	Tryp Therapeutics Inc. completed the acquisition of Exopharm Limited in a reverse merger transaction.
26/02/24	Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023
28/11/23	Exopharm to Cut CEO Role Amid Cost Reductions
27/11/23	Exopharm Limited Announces Ian Dixon's Employment as CEO Expects to End in Early Calendar Year 2024
29/08/23	Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023
22/06/23	Exopharm Limited Announces Executive Changes
28/04/23	Exopharm Achieves Initial Success With Exosome Products; Shares Fall 21%
09/03/23	Exopharm Secures R&D Cash Loan Advance from Radium Capital
09/03/23	Exopharm Limited announced that it has received AUD 1 million in funding
26/02/23	Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022
22/02/23	Exopharm Limited Announces Board Changes
13/02/23	Exopharm Limited announced that it expects to receive AUD 0.6 million in funding
20/12/22	Exopharm Limited Announces Resignation of Elizabeth McGregor as Non-Executive Director
16/11/22	Sartorius BIA Separations and Exopharm Ltd Testing the Synergy of Exopharm's Patented LEAP Technology Together with Bia's Unique Cim (Convective Interaction Media) Monolith Chromatography for Improved Large- Scale Exosome Production and Commercialization
13/11/22	Exopharm Limited Will Commence LEAP Technology Transfer to AIRM under MSA
27/10/22	Exopharm Receives $2.6 Million R&D Tax Rebate
28/09/22	Exopharm Says Drug Product Safe After Animal Testing
28/09/22	Exopharm Limited Announces Study Results Indicate Exosomes Safe for Clinical Pursuit
31/08/22	Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2022
30/08/22	Exopharm Limited Auditor Raises 'Going Concern' Doubt